We narrowed to 304 results for: LAS

#51084-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-hSyn1-GCaMP6s-P2A-nls-dTomato (#51084). In addition to the viral particles, you will also receive purified AAV-hSyn1-GCaMP6s-P2A-nls-dTomato plasmid DNA. GCaMP6s calcium sensor and bicistronic, physically separate nuclear localized dTomato expression under a human synapsin1 promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Jonathan Ting

June 21, 2017

Academic Institutions and Nonprofits only

#37825-AAV2.T

Ready-to-use AAV2 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

May 29, 2019

Academic Institutions and Nonprofits only

#100054-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (#100054). In addition to the viral particles, you will also receive purified pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 plasmid DNA. CAG-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

March 7, 2018

Academic Institutions and Nonprofits only

#105545-AAV1

Ready-to-use AAV1 particles produced from pAAV.CMV.HI.eGFP-Cre.WPRE.SV40 (#105545). In addition to the viral particles, you will also receive purified pAAV.CMV.HI.eGFP-Cre.WPRE.SV40 plasmid DNA. CMV-driven EGFP-Cre expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#105530-AAV1

Ready-to-use AAV1 particles produced from pAAV.CMV.PI.EGFP.WPRE.bGH (#105530). In addition to the viral particles, you will also receive purified pAAV.CMV.PI.EGFP.WPRE.bGH plasmid DNA. CMV-driven EGFP control. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

March 26, 2019

Academic Institutions and Nonprofits only

#37825-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

May 28, 2019

Academic Institutions and Nonprofits only

#105558-AAV5

Ready-to-use AAV5 particles produced from pENN.AAV.CamKII 0.4.Cre.SV40 (#105558). In addition to the viral particles, you will also receive purified pENN.AAV.CamKII 0.4.Cre.SV40 plasmid DNA. CamKII-driven Cre expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Aug. 9, 2018

Academic Institutions and Nonprofits only

#105549-AAV5

Ready-to-use AAV5 particles produced from pAAV.GFAP.eGFP.WPRE.hGH (#105549). In addition to the viral particles, you will also receive purified pAAV.GFAP.eGFP.WPRE.hGH plasmid DNA. GFAP-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

April 6, 2018

Academic Institutions and Nonprofits only

#100043-AAV9

Ready-to-use AAV9 particles produced from pAAV.synP.DIO.EGFP.WPRE.hGH (#100043). In addition to the viral particles, you will also receive purified pAAV.synP.DIO.EGFP.WPRE.hGH plasmid DNA. Synapsin-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

April 20, 2018

Academic Institutions and Nonprofits only

#105545-AAV8

Ready-to-use AAV8 particles produced from pAAV.CMV.HI.eGFP-Cre.WPRE.SV40 (#105545). In addition to the viral particles, you will also receive purified pAAV.CMV.HI.eGFP-Cre.WPRE.SV40 plasmid DNA. CMV-driven EGFP-Cre expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#37825-AAV8.T

Ready-to-use AAV8 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

May 29, 2019

Academic Institutions and Nonprofits only

#105552-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.hSyn.TurboRFP.WPRE.RBG (#105552). In addition to the viral particles, you will also receive purified pENN.AAV.hSyn.TurboRFP.WPRE.RBG plasmid DNA. hSynapsin-driven TurboRFP. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

July 25, 2018

Academic Institutions and Nonprofits only

#51082-AAV1

Ready-to-use AAV1 particles produced from AAV-EF1a-DIO-GCaMP6s-P2A-nls-dTomato (#51082). In addition to the viral particles, you will also receive purified AAV-EF1a-DIO-GCaMP6s-P2A-nls-dTomato plasmid DNA. GCaMP6s calcium sensor and bicistronic, physically separate nuclear localized dTomato expression under the EF1a promoter. These AAV preparations are suitable purity for injection into animals.

Jonathan Ting

Sept. 19, 2017

Academic Institutions and Nonprofits only

#37825-AAVrg.T

Ready-to-use AAV Retrograde trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. GFP expression control. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

July 12, 2019

Academic Institutions and Nonprofits only

#51085-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn1-GCaMP6f-P2A-nls-dTomato (#51085). In addition to the viral particles, you will also receive purified AAV-hSyn1-GCaMP6f-P2A-nls-dTomato plasmid DNA. GCaMP6f calcium sensor and bicistronic, physically separate nuclear localized dTomato expression under the Synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Jonathan Ting

Sept. 21, 2017

Academic Institutions and Nonprofits only

#37825-AAV5.T

Ready-to-use AAV5 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

May 29, 2019

Academic Institutions and Nonprofits only

#107788-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV.rTH.PI.Cre.SV40 (#107788). In addition to the viral particles, you will also receive purified AAV.rTH.PI.Cre.SV40 plasmid DNA. rTH promoter driving Cre expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

May 26, 2020

Academic Institutions and Nonprofits only

#26976-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn-hChR2(H134R)-mCherry (#26976). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-mCherry plasmid DNA. Synapsin-driven, humanized channelrhodopsin H134R mutant, fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Oct. 9, 2019

Academic Institutions and Nonprofits only

#232351-AAV5

Ready-to-use AAV5 particles produced from pAAV-ATLASsnCre (#232351). In addition to the viral particles, you will also receive purified pAAV-ATLASsnCre plasmid DNA. Syn-driven, ATLASsnCre expression. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Rivera et al Nat Methods. 2025 May;22(5):1101-1111. d

Sept. 22, 2025

Academic Institutions and Nonprofits only

#105540-AAV5

Ready-to-use AAV5 particles produced from pENN.AAV.hSyn.HI.eGFP-Cre.WPRE.SV40 (#105540). In addition to the viral particles, you will also receive purified pENN.AAV.hSyn.HI.eGFP-Cre.WPRE.SV40 plasmid DNA. Expression of EGFP-Cre from hSyn promoter. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

May 26, 2020

Academic Institutions and Nonprofits only